Charles River Laboratories Intl. Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while Vanguard Total World Stock Index Fund ETF trades at $157.01. Which is the better fit depends on your goals.
| CRL | VT | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $233.60 | $159.35 |
52-Week Low | $145.57 | $128.41 |
Enterprise Value | $14.00B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
VT trades at $155.81, down 1.15% today, with technical indicators showing a neutral to bearish bias. The ETF offers global diversification with over 10,000 holdings and a 1.6% dividend yield, but key valuation metrics like P/E and P/S are unavailable. Recent news highlights comparisons with competing global ETFs, emphasizing VT's broad exposure versus lower-cost alternatives.
Outlook remains balanced; broad diversification supports long-term stability, but expense ratio competition and neutral technical signals suggest limited near-term catalysts. Risks include global market volatility and fee pressure from rivals like SCHF and SPDW.
Trailing returns across standard periods
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →